beta

ADMS

Adamas Pharmaceuticals Inc.

Adms

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 03-03-2019 after market close 11-01-2018 after market close 08-02-2018 after market close 05-03-2018 after market close 02-22-2018 after market close 11-02-2017 after market close 08-08-2017 after market close 05-09-2017 after market close
Actual EPS -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.06 -1.22 -1.26 -1.35 -1.27 -1.04 -0.93 -0.72
Consensus EPS -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.34 -1.41 -1.38 -1.15 -1.03 -0.85 -0.72
Estimated EPS -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.36 -1.34 -1.41 -1.38 -1.15 -1.03 -0.85 -0.72
Number of Estimates 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 5 5 4 3 3 3
EPS Surprise $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.30 $0.12 $0.15 $0.03 -$0.12 -$0.01 -$0.08

Stats

Summary

Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The Company is developing its wholly-owned product candidate, ADS-5102.

Market Cap: 951 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.adamaspharma.com

Shares Outstanding: 22.8 Million

Float: 22.4 Million

Dividend: 0.0 (0.0%)

Beta: 1.335078

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 7.42 Million

Ethical Flags

Animal testing

Longest drawdown: 481 trading days

From: 2015-12-23 To: 2017-11-20

Lowest Point:

FDA OKs Merck KGaA's MS med Mavenclad

via: SeekingAlpha at 2019-03-30 13:00:54:000

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more … read more...

FDA OKs Merck KGaA's MS med Mavenclad

via: SeekingAlpha at 2019-03-30 13:00:54:000

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more … read more...

FDA OKs Merck KGaA's MS med Mavenclad

via: SeekingAlpha at 2019-03-30 13:00:54:000

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more … read more...

FDA OKs Merck KGaA's MS med Mavenclad

via: SeekingAlpha at 2019-03-30 13:00:54:000

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more … read more...

FDA OKs Novartis' MS med Mayzent

via: SeekingAlpha at 2019-03-27 03:22:46:000

The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio… read more...

FDA OKs Novartis' MS med Mayzent

via: SeekingAlpha at 2019-03-27 03:22:46:000

The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio… read more...

FDA OKs Novartis' MS med Mayzent

via: SeekingAlpha at 2019-03-27 03:22:46:000

The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio… read more...

Adamas Beats On Earnings But Misses On Conference Call

via: SeekingAlpha at 2019-03-11 07:37:37:000

Adamas Pharmaceuticals ( ADMS ), recently announced their Q4/2018 earnings report revealing another beat on revenue and EPS. The company publicized GOCOVRI net sales of roughly $13.3M for Q4 of 2018 (Figure 3), with approximately 5,730 prescriptions ( 4,740 in Q3 ) sold. Adamas was able to… read more...

Adamas Beats On Earnings But Misses On Conference Call

via: SeekingAlpha at 2019-03-11 07:37:37:000

Adamas Pharmaceuticals ( ADMS ), recently announced their Q4/2018 earnings report revealing another beat on revenue and EPS. The company publicized GOCOVRI net sales of roughly $13.3M for Q4 of 2018 (Figure 3), with approximately 5,730 prescriptions ( 4,740 in Q3 ) sold. Adamas was able to… read more...

Adamas Beats On Earnings But Misses On Conference Call

via: SeekingAlpha at 2019-03-11 07:37:37:000

Adamas Pharmaceuticals ( ADMS ), recently announced their Q4/2018 earnings report revealing another beat on revenue and EPS. The company publicized GOCOVRI net sales of roughly $13.3M for Q4 of 2018 (Figure 3), with approximately 5,730 prescriptions ( 4,740 in Q3 ) sold. Adamas was able to… read more...

Midday movers and shakers

via: SeekingAlpha at 2019-03-05 07:53:21:000

Gainers: Document Security Systems (NYSEMKT: DSS ) +57% . Cool Holdings (NASDAQ: AWSM ) +38% . Fuwei Films (NASDAQ: FFHL ) +30% . China Rapid Finance (NYSE: XRF ) +23% . Ctrip.com International (NASDAQ: CTRP ) +21% . Aqua Metals (NASDAQ: AQMS ) +18% . BioHiTech Global (NASDAQ: … read more...

Midday movers and shakers

via: SeekingAlpha at 2019-03-05 07:53:21:000

Gainers: Document Security Systems (NYSEMKT: DSS ) +57% . Cool Holdings (NASDAQ: AWSM ) +38% . Fuwei Films (NASDAQ: FFHL ) +30% . China Rapid Finance (NYSE: XRF ) +23% . Ctrip.com International (NASDAQ: CTRP ) +21% . Aqua Metals (NASDAQ: AQMS ) +18% . BioHiTech Global (NASDAQ: … read more...

Midday movers and shakers

via: SeekingAlpha at 2019-03-05 07:53:21:000

Gainers: Document Security Systems (NYSEMKT: DSS ) +57% . Cool Holdings (NASDAQ: AWSM ) +38% . Fuwei Films (NASDAQ: FFHL ) +30% . China Rapid Finance (NYSE: XRF ) +23% . Ctrip.com International (NASDAQ: CTRP ) +21% . Aqua Metals (NASDAQ: AQMS ) +18% . BioHiTech Global (NASDAQ: … read more...

AFH, HTZ and WB among premarket losers

via: SeekingAlpha at 2019-03-05 04:16:54:000

Atlas Financial Holdings (NASDAQ: AFH ) -49% on Q4 earnings . More news on: Atlas Financial Holdings, Adamas Pharmaceuticals, Inc., China Finance Online Co. Limited, Stocks on the move, Read more … read more...

AFH, HTZ and WB among premarket losers

via: SeekingAlpha at 2019-03-05 04:16:54:000

Atlas Financial Holdings (NASDAQ: AFH ) -49% on Q4 earnings . More news on: Atlas Financial Holdings, Adamas Pharmaceuticals, Inc., China Finance Online Co. Limited, Stocks on the move, Read more … read more...

AFH, HTZ and WB among premarket losers

via: SeekingAlpha at 2019-03-05 04:16:54:000

Atlas Financial Holdings (NASDAQ: AFH ) -49% on Q4 earnings . More news on: Atlas Financial Holdings, Adamas Pharmaceuticals, Inc., China Finance Online Co. Limited, Stocks on the move, Read more … read more...

Adamas Pharma down 29% premarket on slow Gocovri ramp, downgrades

via: SeekingAlpha at 2019-03-05 02:25:26:000

Adamas Pharmaceuticals (NASDAQ: ADMS ) slumps 29% premarket on light volume on the heels of its Q4 report that appeared to disappoint investors despite meeting preannounced Q4 results released in early January. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthc… read more...

Adamas Pharma down 29% premarket on slow Gocovri ramp, downgrades

via: SeekingAlpha at 2019-03-05 02:25:26:000

Adamas Pharmaceuticals (NASDAQ: ADMS ) slumps 29% premarket on light volume on the heels of its Q4 report that appeared to disappoint investors despite meeting preannounced Q4 results released in early January. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthc… read more...

Adamas Pharma down 29% premarket on slow Gocovri ramp, downgrades

via: SeekingAlpha at 2019-03-05 02:25:26:000

Adamas Pharmaceuticals (NASDAQ: ADMS ) slumps 29% premarket on light volume on the heels of its Q4 report that appeared to disappoint investors despite meeting preannounced Q4 results released in early January. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthc… read more...

Adamas Pharmaceuticals, Inc. (ADMS) CEO Greg Went on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-04 15:26:07:000

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2018 Earnings Conference Call March 4, 2019 4:30 p.m. ET Company Participants Greg Went - Chairman and CEO Alf Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Participants David Amsellem - Piper Jaffray Tim Lug… read more...

Adamas Pharmaceuticals, Inc. (ADMS) CEO Greg Went on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-04 15:26:07:000

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2018 Earnings Conference Call March 4, 2019 4:30 p.m. ET Company Participants Greg Went - Chairman and CEO Alf Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Participants David Amsellem - Piper Jaffray Tim Lug… read more...

Adamas Pharmaceuticals, Inc. (ADMS) CEO Greg Went on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-04 15:26:07:000

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2018 Earnings Conference Call March 4, 2019 4:30 p.m. ET Company Participants Greg Went - Chairman and CEO Alf Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Participants David Amsellem - Piper Jaffray Tim Lug… read more...

Adamas Pharma beats by $0.32, beats on revenue

via: SeekingAlpha at 2019-03-04 11:38:12:000

Adamas Pharma (NASDAQ: ADMS ): Q4 GAAP EPS of -$1.06 beats by $0.32 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Amarin: Rating Sell With $5 Price Target, 2-Year Timeframe (70% Downside)

via: SeekingAlpha at 2019-01-27 20:04:39:000

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati… read more...

Amarin: Rating Sell With $5 Price Target, 2-Year Timeframe (70% Downside)

via: SeekingAlpha at 2019-01-27 20:04:39:000

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati… read more...

Amarin: Rating Sell With $5 Price Target, 2-Year Timeframe (70% Downside)

via: SeekingAlpha at 2019-01-27 20:04:39:000

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati… read more...

Recent Adamas Report Provides Projections And Trends To Profitability

via: SeekingAlpha at 2019-01-10 13:49:36:000

Source ADMS On Sunday, January 6th, Adamas Pharmaceuticals, Inc. ( ADMS ), provided preliminary 2018 sales results for GOCOVRI and outlined key business priorities for 2019. The company reported GOCOVRI preliminary net sales of approximately $13.3M for the fourth quarter of 2018, with … read more...

Recent Adamas Report Provides Projections And Trends To Profitability

via: SeekingAlpha at 2019-01-10 13:49:36:000

Source ADMS On Sunday, January 6th, Adamas Pharmaceuticals, Inc. ( ADMS ), provided preliminary 2018 sales results for GOCOVRI and outlined key business priorities for 2019. The company reported GOCOVRI preliminary net sales of approximately $13.3M for the fourth quarter of 2018, with … read more...

Recent Adamas Report Provides Projections And Trends To Profitability

via: SeekingAlpha at 2019-01-10 13:49:36:000

Source ADMS On Sunday, January 6th, Adamas Pharmaceuticals, Inc. ( ADMS ), provided preliminary 2018 sales results for GOCOVRI and outlined key business priorities for 2019. The company reported GOCOVRI preliminary net sales of approximately $13.3M for the fourth quarter of 2018, with … read more...

Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

via: SeekingAlpha at 2019-01-07 10:13:49:000

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...

Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

via: SeekingAlpha at 2019-01-07 10:13:49:000

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...

Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

via: SeekingAlpha at 2019-01-07 10:13:49:000

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...

Adamas up 9% on 2018 GOCOVRI sales

via: SeekingAlpha at 2019-01-07 08:45:20:000

Adamas Pharmaceuticals (NASDAQ: ADMS ) outlines key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI (amantadine) extended release capsules. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Adamas up 9% on 2018 GOCOVRI sales

via: SeekingAlpha at 2019-01-07 08:45:20:000

Adamas Pharmaceuticals (NASDAQ: ADMS ) outlines key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI (amantadine) extended release capsules. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Adamas up 9% on 2018 GOCOVRI sales

via: SeekingAlpha at 2019-01-07 08:45:20:000

Adamas Pharmaceuticals (NASDAQ: ADMS ) outlines key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI (amantadine) extended release capsules. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts

via: SeekingAlpha at 2018-12-28 18:37:48:000

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...

Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts

via: SeekingAlpha at 2018-12-28 18:37:48:000

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...

Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts

via: SeekingAlpha at 2018-12-28 18:37:48:000

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...

Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts

via: SeekingAlpha at 2018-12-28 18:37:48:000

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...

Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts

via: SeekingAlpha at 2018-12-28 18:37:48:000

It has been a tough year for Acorda Therapeutics ( ACOR ) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3 , but with generics grabbing the lion's share of the market, we can expect … read more...

Adamas Knife Continues To Fall As Value Continues To Rise

via: SeekingAlpha at 2018-12-26 14:59:04:000

Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS… read more...

Adamas Knife Continues To Fall As Value Continues To Rise

via: SeekingAlpha at 2018-12-26 14:59:04:000

Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS… read more...

Adamas Knife Continues To Fall As Value Continues To Rise

via: SeekingAlpha at 2018-12-26 14:59:04:000

Adamas Pharmaceuticals, Inc. ( ADMS ) has had a volatile 2018 experiencing all-time highs and lows. I recently published an article on Adamas reviewing the results of the company's 3rd quarter earnings report and subsequent demolition of the share price. In that article, I categorized ADMS… read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Adamas Gets Beat Down For Beating Q3 Estimates

via: SeekingAlpha at 2018-11-11 17:00:12:000

Source Company Overview Adamas Pharmaceuticals, Inc. ( ADMS ) is a commercial stage pharmaceutical company that specializes in developing chrono-synchronous therapies for chronic neurologic disorders. Figure 1 illustrates the Adamas portfolio that focuses around their principal drug… read more...

Adamas Gets Beat Down For Beating Q3 Estimates

via: SeekingAlpha at 2018-11-11 17:00:12:000

Source Company Overview Adamas Pharmaceuticals, Inc. ( ADMS ) is a commercial stage pharmaceutical company that specializes in developing chrono-synchronous therapies for chronic neurologic disorders. Figure 1 illustrates the Adamas portfolio that focuses around their principal drug… read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Healthcare and Tech top list of midday movers (11/02/2018)

via: SeekingAlpha at 2018-11-02 12:47:27:000

More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...

Healthcare and Tech top list of midday movers (11/02/2018)

via: SeekingAlpha at 2018-11-02 12:47:27:000

More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...

Healthcare and Tech top list of midday movers (11/02/2018)

via: SeekingAlpha at 2018-11-02 12:47:27:000

More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...

Adamas Pharma down 22% after Q3 report, slow market penetration for Gocovri

via: SeekingAlpha at 2018-11-02 10:42:38:000

Adamas Pharmaceuticals ( ADMS -21.9% ) slumps on nearly double normal volume in reaction to its Q3 results released after the close yesterday. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more… read more...

Adamas Pharma down 22% after Q3 report, slow market penetration for Gocovri

via: SeekingAlpha at 2018-11-02 10:42:38:000

Adamas Pharmaceuticals ( ADMS -21.9% ) slumps on nearly double normal volume in reaction to its Q3 results released after the close yesterday. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more… read more...

Adamas Pharma down 22% after Q3 report, slow market penetration for Gocovri

via: SeekingAlpha at 2018-11-02 10:42:38:000

Adamas Pharmaceuticals ( ADMS -21.9% ) slumps on nearly double normal volume in reaction to its Q3 results released after the close yesterday. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more… read more...

Adamas Pharmaceuticals' (ADMS) Greg Went on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:16:05:000

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Ashleigh Barreto Director-Investor Relations and Corporate Communications Greg Went Chairman and Chief Executive Officer Alf Merriweather Chief F… read more...

Adamas Pharmaceuticals' (ADMS) Greg Went on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:16:05:000

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Ashleigh Barreto Director-Investor Relations and Corporate Communications Greg Went Chairman and Chief Executive Officer Alf Merriweather Chief F… read more...

Adamas Pharmaceuticals' (ADMS) Greg Went on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 22:16:05:000

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Ashleigh Barreto Director-Investor Relations and Corporate Communications Greg Went Chairman and Chief Executive Officer Alf Merriweather Chief F… read more...

Adamas Pharma beats by $0.12, beats on revenue

via: SeekingAlpha at 2018-11-01 16:04:06:000

Adamas Pharma (NASDAQ: ADMS ): Q3 GAAP EPS of -$1.22 beats by $0.12 . Revenue of $10.6M beats by $0.46M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Your Daily Pharma Scoop: Adamas GOCOVRI Shows Positive Effect, Affimed Down On Clinical Hold

via: SeekingAlpha at 2018-10-09 13:47:50:000

Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths … read more...

Your Daily Pharma Scoop: Adamas GOCOVRI Shows Positive Effect, Affimed Down On Clinical Hold

via: SeekingAlpha at 2018-10-09 13:47:50:000

Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths … read more...

Your Daily Pharma Scoop: Adamas GOCOVRI Shows Positive Effect, Affimed Down On Clinical Hold

via: SeekingAlpha at 2018-10-09 13:47:50:000

Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths … read more...

VistaGen: Expensive At 12x Its Book Value Per Share

via: SeekingAlpha at 2018-10-09 09:38:38:000

After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote… read more...

VistaGen: Expensive At 12x Its Book Value Per Share

via: SeekingAlpha at 2018-10-09 09:38:38:000

After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote… read more...

VistaGen: Expensive At 12x Its Book Value Per Share

via: SeekingAlpha at 2018-10-09 09:38:38:000

After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote… read more...

Adamas Pharma's Gocovri shows long-term treatment effect in late-stage Parkinson's study

via: SeekingAlpha at 2018-10-08 09:56:52:000

Final results from a two-year open-label Phase 3 clinical trial, EASE LID 2 , evaluating Adamas Pharmaceuticals' ( ADMS -3.1% ) GOCOVRI (amantadine) in patients with Parkinson's disease (PD) showed a sustained treatment effect. The data were presented at the International Congress of P… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-05 08:48:55:000

Natera (NASDAQ: NTRA ) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan. More news on: Natera, Evolent Health, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-05 08:48:55:000

Natera (NASDAQ: NTRA ) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan. More news on: Natera, Evolent Health, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-05 08:48:55:000

Natera (NASDAQ: NTRA ) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan. More news on: Natera, Evolent Health, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more … read more...

Adamas Pharmaceuticals, Inc. (ADMS) Gregory Went on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-03 20:32:06:000

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2018 Results Earnings Conference Call August 02, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Founder, Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patn… read more...

Adamas Pharmaceuticals, Inc. (ADMS) Gregory Went on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-03 20:32:06:000

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2018 Results Earnings Conference Call August 02, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Founder, Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patn… read more...

Adamas Pharmaceuticals, Inc. (ADMS) Gregory Went on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-03 20:32:06:000

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2018 Results Earnings Conference Call August 02, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Founder, Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patn… read more...

Adamas Pharmaceuticals, Inc. (ADMS) Gregory Went on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-03 20:32:06:000

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2018 Results Earnings Conference Call August 02, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Founder, Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patn… read more...

Adamas Pharma beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-08-02 16:02:38:000

Adamas Pharma (NASDAQ: ADMS ): Q2 EPS of -$1.26 beats by $0.15 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adamas Pharma beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-08-02 16:02:38:000

Adamas Pharma (NASDAQ: ADMS ): Q2 EPS of -$1.26 beats by $0.15 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-16 07:54:19:000

Cellectis S.A. (NASDAQ: CLLS ) initiated with Buy rating and $50 (76% upside) price target at Barclays. Shares up 8% premarket. More news on: Cellectis S.A., Aptinyx, AVROBIO, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-16 07:54:19:000

Cellectis S.A. (NASDAQ: CLLS ) initiated with Buy rating and $50 (76% upside) price target at Barclays. Shares up 8% premarket. More news on: Cellectis S.A., Aptinyx, AVROBIO, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-16 07:54:19:000

Cellectis S.A. (NASDAQ: CLLS ) initiated with Buy rating and $50 (76% upside) price target at Barclays. Shares up 8% premarket. More news on: Cellectis S.A., Aptinyx, AVROBIO, Healthcare stocks news, Stocks on the move, , Read more … read more...

Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap

via: SeekingAlpha at 2018-06-27 13:00:17:000

With an impressive team of professionals, tons of cash in the balance sheet, and three product candidates, Aptinyx (APTX) looks like an opportunity. The fact that remarkable underwriters worked with the company is the first feature to like. Have a look at the image below: Source: S-1 Bus… read more...

Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap

via: SeekingAlpha at 2018-06-27 13:00:17:000

With an impressive team of professionals, tons of cash in the balance sheet, and three product candidates, Aptinyx (APTX) looks like an opportunity. The fact that remarkable underwriters worked with the company is the first feature to like. Have a look at the image below: Source: S-1 Bus… read more...

Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap

via: SeekingAlpha at 2018-06-27 13:00:17:000

With an impressive team of professionals, tons of cash in the balance sheet, and three product candidates, Aptinyx (APTX) looks like an opportunity. The fact that remarkable underwriters worked with the company is the first feature to like. Have a look at the image below: Source: S-1 Bus… read more...

3 Things In Biotech, June 25: Bad News For Checkpoints In Bladder. Good News In Liver!

via: SeekingAlpha at 2018-06-25 23:59:14:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. The FDA drops the hammer (just a bit!) on Roche and Merck Company: Roche ( OTCQX:RHHBF … read more...

My Top Picks With A 1-Year Time Frame

via: SeekingAlpha at 2018-06-14 13:43:21:000

In general, I am against trying to predict where stocks will go within the next year. I consider it too short of a time frame for many stocks and prefer to invest mostly on long-term fundamentals. For the few who have read multiple of my articles, you'll notice that most of them have 2-3 year … read more...

My Top Picks With A 1-Year Time Frame

via: SeekingAlpha at 2018-06-14 13:43:21:000

In general, I am against trying to predict where stocks will go within the next year. I consider it too short of a time frame for many stocks and prefer to invest mostly on long-term fundamentals. For the few who have read multiple of my articles, you'll notice that most of them have 2-3 year … read more...

My Top Picks With A 1-Year Time Frame

via: SeekingAlpha at 2018-06-14 13:43:21:000

In general, I am against trying to predict where stocks will go within the next year. I consider it too short of a time frame for many stocks and prefer to invest mostly on long-term fundamentals. For the few who have read multiple of my articles, you'll notice that most of them have 2-3 year … read more...

What Does The Rate Hike Mean For Stocks - Cramer's Mad Money (6/13/18)

via: SeekingAlpha at 2018-06-14 07:38:59:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 13. As the Fed has decided to make more rate hikes during the year, buyers became cautious and the market dipped. "Recognize that owning stocks just got harder. Higher rates are not a po… read more...

What Does The Rate Hike Mean For Stocks - Cramer's Mad Money (6/13/18)

via: SeekingAlpha at 2018-06-14 07:38:59:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 13. As the Fed has decided to make more rate hikes during the year, buyers became cautious and the market dipped. "Recognize that owning stocks just got harder. Higher rates are not a po… read more...

What Does The Rate Hike Mean For Stocks - Cramer's Mad Money (6/13/18)

via: SeekingAlpha at 2018-06-14 07:38:59:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday , June 13. As the Fed has decided to make more rate hikes during the year, buyers became cautious and the market dipped. "Recognize that owning stocks just got harder. Higher rates are not a po… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

via: SeekingAlpha at 2018-05-22 12:03:38:000

Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

via: SeekingAlpha at 2018-05-22 12:03:38:000

Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

via: SeekingAlpha at 2018-05-22 12:03:38:000

Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

Adamas Pharmaceuticals: Interesting Over The Long Term

via: SeekingAlpha at 2018-05-18 12:31:37:000

Adamas Pharmaceuticals (ADMS) has the only approved drug in levodopa induced dyskinesia for Parkinsons Disease patients. That drug, Gocovri, is an extended release formulation of a generic drug named amantadine, and it is also in late stage development for walking impairment in multipl… read more...

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions

via: SeekingAlpha at 2018-05-14 11:37:23:000

Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions

via: SeekingAlpha at 2018-05-14 11:37:23:000

Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

via: SeekingAlpha at 2018-05-07 15:40:31:000

Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

via: SeekingAlpha at 2018-05-07 15:40:31:000

Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Adamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-03 21:26:02:000

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2018 Results Earnings Conference Call May 3, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patni - Chief Med… read more...

Adamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-03 21:26:02:000

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2018 Results Earnings Conference Call May 3, 2018, 04:30 PM ET Executives Ashleigh Barreto - Director, Corporate Communications & IR Gregory Went - Chairman and CEO Alfred Merriweather - CFO Richard King - COO Rajiv Patni - Chief Med… read more...

Adamas Pharma beats by $0.02, beats on revenue

via: SeekingAlpha at 2018-05-03 16:40:59:000

Adamas Pharma (NASDAQ: ADMS ): Q1 EPS of -$1.35 beats by $0.02 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adamas Pharma beats by $0.02, beats on revenue

via: SeekingAlpha at 2018-05-03 16:40:59:000

Adamas Pharma (NASDAQ: ADMS ): Q1 EPS of -$1.35 beats by $0.02 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

via: SeekingAlpha at 2018-05-01 02:41:27:000

Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

via: SeekingAlpha at 2018-05-01 02:41:27:000

Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

JF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection

via: SeekingAlpha at 2018-04-24 01:42:47:000

Welcome to the twelfth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size o… read more...

JF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection

via: SeekingAlpha at 2018-04-24 01:42:47:000

Welcome to the twelfth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size o… read more...

3 Things In Biotech, April 22: All These 'A' Companies

via: SeekingAlpha at 2018-04-23 09:04:45:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, April 22: All These 'A' Companies

via: SeekingAlpha at 2018-04-23 09:04:45:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Your Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis Results

via: SeekingAlpha at 2018-04-20 08:00:00:000

Analysis focus: Adamas Today, we will discuss Adamas Pharmaceuticals (ADMS), which is up sharply after reporting final results from the two-year phase 3 study of GOCOVRI in Parkinson's Disease ((PD)) patients who have dyskinesia because of long-term levodopa usage. GOCOVRI was approved… read more...

Your Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis Results

via: SeekingAlpha at 2018-04-20 08:00:00:000

Analysis focus: Adamas Today, we will discuss Adamas Pharmaceuticals (ADMS), which is up sharply after reporting final results from the two-year phase 3 study of GOCOVRI in Parkinson's Disease ((PD)) patients who have dyskinesia because of long-term levodopa usage. GOCOVRI was approved… read more...

JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

via: SeekingAlpha at 2018-04-17 11:46:21:000

Welcome to the eleventh edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

via: SeekingAlpha at 2018-04-17 11:46:21:000

Welcome to the eleventh edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Biotech Forum: The Week Ahead

via: SeekingAlpha at 2018-04-16 12:05:10:000

"Life is what happens to us while we are making other plans." - Allen Saunders While the major biotech firms do not start reporting quarterly numbers until later this month, they benefited from the overall solid first week of full first quarter earnings reports crossing the wires this week… read more...

Biotech Forum: The Week Ahead

via: SeekingAlpha at 2018-04-16 12:05:10:000

"Life is what happens to us while we are making other plans." - Allen Saunders While the major biotech firms do not start reporting quarterly numbers until later this month, they benefited from the overall solid first week of full first quarter earnings reports crossing the wires this week… read more...

Adamas Pharma (ADMS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-02-16 13:01:29:000

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Adamas Pharma (ADMS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-02-16 13:01:29:000

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Study data show that Parkinson's patients could switch to Adamas Pharma's Gocovri without interruption; shares up 3%

via: SeekingAlpha at 2018-02-08 10:41:22:000

A subgroup analysis of Parkinson's disease (PD) patients enrolled in the ongoing open-label EASE LID 2 study who were still experiencing uncontrolled involuntary movement showed improvements after switching to Adamas Pharmaceuticals' ( ADMS +2.5% ) GOCOVRI (amantadine) extended-release c… read more...

Study data show that Parkinson's patients could switch to Adamas Pharma's Gocovri without interruption; shares up 3%

via: SeekingAlpha at 2018-02-08 10:41:22:000

A subgroup analysis of Parkinson's disease (PD) patients enrolled in the ongoing open-label EASE LID 2 study who were still experiencing uncontrolled involuntary movement showed improvements after switching to Adamas Pharmaceuticals' ( ADMS +2.5% ) GOCOVRI (amantadine) extended-release c… read more...

Study data show that Parkinson's patients could switch to Adamas Pharma's Gocovri without interruption; shares up 3%

via: SeekingAlpha at 2018-02-08 10:41:22:000

A subgroup analysis of Parkinson's disease (PD) patients enrolled in the ongoing open-label EASE LID 2 study who were still experiencing uncontrolled involuntary movement showed improvements after switching to Adamas Pharmaceuticals' ( ADMS +2.5% ) GOCOVRI (amantadine) extended-release c… read more...

Study data show that Parkinson's patients could switch to Adamas Pharma's Gocovri without interruption; shares up 3%

via: SeekingAlpha at 2018-02-08 10:41:22:000

A subgroup analysis of Parkinson's disease (PD) patients enrolled in the ongoing open-label EASE LID 2 study who were still experiencing uncontrolled involuntary movement showed improvements after switching to Adamas Pharmaceuticals' ( ADMS +2.5% ) GOCOVRI (amantadine) extended-release c… read more...

Study data show that Parkinson's patients could switch to Adamas Pharma's Gocovri without interruption; shares up 3%

via: SeekingAlpha at 2018-02-08 10:41:22:000

A subgroup analysis of Parkinson's disease (PD) patients enrolled in the ongoing open-label EASE LID 2 study who were still experiencing uncontrolled involuntary movement showed improvements after switching to Adamas Pharmaceuticals' ( ADMS +2.5% ) GOCOVRI (amantadine) extended-release c… read more...

Study data show that Parkinson's patients could switch to Adamas Pharma's Gocovri without interruption; shares up 3%

via: SeekingAlpha at 2018-02-08 10:41:22:000

A subgroup analysis of Parkinson's disease (PD) patients enrolled in the ongoing open-label EASE LID 2 study who were still experiencing uncontrolled involuntary movement showed improvements after switching to Adamas Pharmaceuticals' ( ADMS +2.5% ) GOCOVRI (amantadine) extended-release c… read more...

Biotech Forum Daily Digest For January 24th

via: SeekingAlpha at 2018-01-24 10:13:06:000

No matter how long you train someone to be brave, you never know if they are or not until something real happens . Veronica Roth, Insurgent The biotech sector got off to a stunning start to the trading week on Monday. Celgene ( CELG ) acquired Juno Therapeutics ( JUN… read more...

Biotech Forum Daily Digest For January 24th

via: SeekingAlpha at 2018-01-24 10:13:06:000

No matter how long you train someone to be brave, you never know if they are or not until something real happens . Veronica Roth, Insurgent The biotech sector got off to a stunning start to the trading week on Monday. Celgene ( CELG ) acquired Juno Therapeutics ( JUN… read more...

Biotech Forum Daily Digest For January 24th

via: SeekingAlpha at 2018-01-24 10:13:06:000

No matter how long you train someone to be brave, you never know if they are or not until something real happens . Veronica Roth, Insurgent The biotech sector got off to a stunning start to the trading week on Monday. Celgene ( CELG ) acquired Juno Therapeutics ( JUN… read more...

Biotech Forum Daily Digest For January 24th

via: SeekingAlpha at 2018-01-24 10:13:06:000

No matter how long you train someone to be brave, you never know if they are or not until something real happens . Veronica Roth, Insurgent The biotech sector got off to a stunning start to the trading week on Monday. Celgene ( CELG ) acquired Juno Therapeutics ( JUN… read more...

Biotech Forum Daily Digest For January 24th

via: SeekingAlpha at 2018-01-24 10:13:06:000

No matter how long you train someone to be brave, you never know if they are or not until something real happens . Veronica Roth, Insurgent The biotech sector got off to a stunning start to the trading week on Monday. Celgene ( CELG ) acquired Juno Therapeutics ( JUN… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform

via: SeekingAlpha at 2018-01-24 08:00:00:000

Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics ( PGNX ). Progenics shares have made a solid start to the year, gaining more than 9.5%. On Monday, the stock closed nearly 4% higher. We first initiated coverage on Progenics in November last year, noti… read more...

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

via: SeekingAlpha at 2018-01-19 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

via: SeekingAlpha at 2018-01-19 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

via: SeekingAlpha at 2018-01-19 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

via: SeekingAlpha at 2018-01-19 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

via: SeekingAlpha at 2018-01-19 08:00:00:000

Analysis of Top Seeking Alpha Coverage: Adamas Today we will Admas Pharmaceuticals' ( ADMS ) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease ((PD)) patients. Adamas is coming off an ex… read more...

Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond

via: SeekingAlpha at 2018-01-15 23:40:02:000

Shares of Adamas Pharmaceuticals ( ADMS ) have more than doubled since April of last year when I suggested readers take positions for the runup to approval and beyond. ADMS data by YCharts Keys to the original bullish thesis included the following: Possession of a broad, differe… read more...

Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond

via: SeekingAlpha at 2018-01-15 23:40:02:000

Shares of Adamas Pharmaceuticals ( ADMS ) have more than doubled since April of last year when I suggested readers take positions for the runup to approval and beyond. ADMS data by YCharts Keys to the original bullish thesis included the following: Possession of a broad, differe… read more...

Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond

via: SeekingAlpha at 2018-01-15 23:40:02:000

Shares of Adamas Pharmaceuticals ( ADMS ) have more than doubled since April of last year when I suggested readers take positions for the runup to approval and beyond. ADMS data by YCharts Keys to the original bullish thesis included the following: Possession of a broad, differe… read more...

Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond

via: SeekingAlpha at 2018-01-15 23:40:02:000

Shares of Adamas Pharmaceuticals ( ADMS ) have more than doubled since April of last year when I suggested readers take positions for the runup to approval and beyond. ADMS data by YCharts Keys to the original bullish thesis included the following: Possession of a broad, differe… read more...

Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond

via: SeekingAlpha at 2018-01-15 23:40:02:000

Shares of Adamas Pharmaceuticals ( ADMS ) have more than doubled since April of last year when I suggested readers take positions for the runup to approval and beyond. ADMS data by YCharts Keys to the original bullish thesis included the following: Possession of a broad, differe… read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2018-01-08 17:35:09:000

Top gainers: SHLM +5.3% . ADMS +4.2% . FSIC +1.3% . AGN +1.3% . GG +1.2% . More news on: A. Schulman, Inc., Adamas Pharmaceuticals, Inc., FS Investment Corporation, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2018-01-08 17:35:09:000

Top gainers: SHLM +5.3% . ADMS +4.2% . FSIC +1.3% . AGN +1.3% . GG +1.2% . More news on: A. Schulman, Inc., Adamas Pharmaceuticals, Inc., FS Investment Corporation, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2018-01-08 17:35:09:000

Top gainers: SHLM +5.3% . ADMS +4.2% . FSIC +1.3% . AGN +1.3% . GG +1.2% . More news on: A. Schulman, Inc., Adamas Pharmaceuticals, Inc., FS Investment Corporation, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2018-01-08 17:35:09:000

Top gainers: SHLM +5.3% . ADMS +4.2% . FSIC +1.3% . AGN +1.3% . GG +1.2% . More news on: A. Schulman, Inc., Adamas Pharmaceuticals, Inc., FS Investment Corporation, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2018-01-08 17:35:09:000

Top gainers: SHLM +5.3% . ADMS +4.2% . FSIC +1.3% . AGN +1.3% . GG +1.2% . More news on: A. Schulman, Inc., Adamas Pharmaceuticals, Inc., FS Investment Corporation, Stocks on the move, Read more … read more...

Biotech Forum Daily Digest: Why We Are Passing On Pulse

via: SeekingAlpha at 2017-12-29 11:15:31:000

It's hard to beat a person who never gives up . Babe Ruth It has been a good year for the overall market and the biotech sector in 2017. Year-over-year earnings growth from the S&P 500 was in the double digits for the first time in several years. GDP growth has accele… read more...

Biotech Forum Daily Digest: Why We Are Passing On Pulse

via: SeekingAlpha at 2017-12-29 11:15:31:000

It's hard to beat a person who never gives up . Babe Ruth It has been a good year for the overall market and the biotech sector in 2017. Year-over-year earnings growth from the S&P 500 was in the double digits for the first time in several years. GDP growth has accele… read more...

Biotech Forum Daily Digest: Why We Are Passing On Pulse

via: SeekingAlpha at 2017-12-29 11:15:31:000

It's hard to beat a person who never gives up . Babe Ruth It has been a good year for the overall market and the biotech sector in 2017. Year-over-year earnings growth from the S&P 500 was in the double digits for the first time in several years. GDP growth has accele… read more...

Biotech Forum Daily Digest: Why We Are Passing On Pulse

via: SeekingAlpha at 2017-12-29 11:15:31:000

It's hard to beat a person who never gives up . Babe Ruth It has been a good year for the overall market and the biotech sector in 2017. Year-over-year earnings growth from the S&P 500 was in the double digits for the first time in several years. GDP growth has accele… read more...

Biotech Forum Daily Digest: Why We Are Passing On Pulse

via: SeekingAlpha at 2017-12-29 11:15:31:000

It's hard to beat a person who never gives up . Babe Ruth It has been a good year for the overall market and the biotech sector in 2017. Year-over-year earnings growth from the S&P 500 was in the double digits for the first time in several years. GDP growth has accele… read more...

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

via: SeekingAlpha at 2017-12-23 11:37:46:000

Analysis of top Seeking Alpha coverage: Biogen Today we will focus on Biogens ( BIIB ) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study. Biogen shares dropped more than 3% on Thursday after the company said that an Independent D… read more...

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

via: SeekingAlpha at 2017-12-23 11:37:46:000

Analysis of top Seeking Alpha coverage: Biogen Today we will focus on Biogens ( BIIB ) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study. Biogen shares dropped more than 3% on Thursday after the company said that an Independent D… read more...

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

via: SeekingAlpha at 2017-12-23 11:37:46:000

Analysis of top Seeking Alpha coverage: Biogen Today we will focus on Biogens ( BIIB ) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study. Biogen shares dropped more than 3% on Thursday after the company said that an Independent D… read more...

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

via: SeekingAlpha at 2017-12-23 11:37:46:000

Analysis of top Seeking Alpha coverage: Biogen Today we will focus on Biogens ( BIIB ) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study. Biogen shares dropped more than 3% on Thursday after the company said that an Independent D… read more...

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

via: SeekingAlpha at 2017-12-23 11:37:46:000

Analysis of top Seeking Alpha coverage: Biogen Today we will focus on Biogens ( BIIB ) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study. Biogen shares dropped more than 3% on Thursday after the company said that an Independent D… read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Biotech Forum Daily Digest: Impacts Of Tax Reform

via: SeekingAlpha at 2017-12-15 13:12:58:000

"Fame is a fickle food upon a shifting plate." - Emily Dickinson It has been a pretty wild ride in biotech land this week. The main biotech indices dropped over one percent on Tuesday, clawed back those losses on Wednesday, only to fall more than one percent in trading Thursday. In early g… read more...

Biotech Forum Daily Digest: Impacts Of Tax Reform

via: SeekingAlpha at 2017-12-15 13:12:58:000

"Fame is a fickle food upon a shifting plate." - Emily Dickinson It has been a pretty wild ride in biotech land this week. The main biotech indices dropped over one percent on Tuesday, clawed back those losses on Wednesday, only to fall more than one percent in trading Thursday. In early g… read more...

Biotech Forum Daily Digest: Impacts Of Tax Reform

via: SeekingAlpha at 2017-12-15 13:12:58:000

"Fame is a fickle food upon a shifting plate." - Emily Dickinson It has been a pretty wild ride in biotech land this week. The main biotech indices dropped over one percent on Tuesday, clawed back those losses on Wednesday, only to fall more than one percent in trading Thursday. In early g… read more...

Biotech Forum Daily Digest: Impacts Of Tax Reform

via: SeekingAlpha at 2017-12-15 13:12:58:000

"Fame is a fickle food upon a shifting plate." - Emily Dickinson It has been a pretty wild ride in biotech land this week. The main biotech indices dropped over one percent on Tuesday, clawed back those losses on Wednesday, only to fall more than one percent in trading Thursday. In early g… read more...

Biotech Forum Daily Digest: Impacts Of Tax Reform

via: SeekingAlpha at 2017-12-15 13:12:58:000

"Fame is a fickle food upon a shifting plate." - Emily Dickinson It has been a pretty wild ride in biotech land this week. The main biotech indices dropped over one percent on Tuesday, clawed back those losses on Wednesday, only to fall more than one percent in trading Thursday. In early g… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX